Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.55 |
| ▸ | PPARA | Q07869 | 11/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7535724 | 0.93 | PPARG (0.62) | PPARGPPARAHDAC1HDAC6ALDH1A1 | |
| SCHEMBL7530906 | 0.91 | PPARG (0.68) | PPARGPPARAHDAC1HDAC6PPARD | |
| SCHEMBL7528891 | 0.90 | PPARG (0.51) | PPARGPPARAHDAC1HDAC6ALDH1A1 | |
| SCHEMBL7530470 | 0.89 | PPARG (0.49) | PPARGPPARAHDAC1HDAC6ALDH1A1 | |
| SCHEMBL7530777 | 0.88 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL7533463 | 0.85 | PPARG (0.78) | PPARGPPARAPPARD | |
| SCHEMBL7527548 | 0.82 | PPARG (0.65) | PPARGPPARAHDAC1HDAC6PPARD | |
| SCHEMBL7529707 | 0.82 | PPARG (0.78) | PPARGPPARAPPARD | |
| SCHEMBL7529020 | 0.81 | PPARG (0.64) | PPARGPPARAHDAC1HDAC6PPARD | |
| SCHEMBL7535386 | 0.81 | PPARG (0.65) | PPARGPPARAPPARDPTPRFPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-01 | — | — | US | claimed |
| US-6468996-B1 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ACTIVATORS; TREATMENT OF DIABETES AND OBESITY. | NOVO NORDISK A/S (DK) | 2002-10-22 | — | — | US | disclosed |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | JEPPESEN LONE (DK) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103188-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885HDAC1 120/4885 |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885HDAC1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.